Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.

Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.

RATIONALE: Increased vascularity and expression of vascular endothelial growth factor (VEGF) are recognized features of the asthmatic airway. The association of vascular remodeling with airway hyperresponsiveness (AHR) is unclear. OBJECTIVE: To assess vascular remodeling and sputum VEGF concentrati...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Siddiqui, S, Sutcliffe, A, Shikotra, A, Woodman, L, Doe, C, McKenna, S, Wardlaw, A, Bradding, P, Pavord, I, Brightling, C
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2007

Παρόμοια τεκμήρια

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
ανά: Brightling, C, κ.ά.
Έκδοση: (2003)

Role of PGE2 in Asthma and Nonasthmatic Eosinophilic Bronchitis
ανά: Beatriz Sastre, κ.ά.
Έκδοση: (2012-01-01)

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.
ανά: Berry, M, κ.ά.
Έκδοση: (2004)

Chemokine concentrations and mast cell chemotactic activity in BAL fluid in patients with eosinophilic bronchitis and asthma, and in normal control subjects.
ανά: Woodman, L, κ.ά.
Έκδοση: (2006)

TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis.
ανά: Brightling, C, κ.ά.
Έκδοση: (2002)

Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma.
ανά: Brightling, C, κ.ά.
Έκδοση: (1999)

Observational study of the natural history of eosinophilic bronchitis.
ανά: Berry, M, κ.ά.
Έκδοση: (2005)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma.
ανά: Brightling, C, κ.ά.
Έκδοση: (2000)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
ανά: Brightling, C, κ.ά.
Έκδοση: (2000)

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
ανά: Green, R, κ.ά.
Έκδοση: (2002)

IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis
ανά: Mistry Vijay, κ.ά.
Έκδοση: (2009-07-01)

Eosinophilic bronchitis is an important cause of chronic cough.
ανά: Brightling, C, κ.ά.
Έκδοση: (1999)

Eosinophilic bronchitis - what is it and why is it important?
ανά: Brightling, C, κ.ά.
Έκδοση: (2000)

Mepolizumab in refractory eosinophilic asthma.
ανά: Pavord, I, κ.ά.
Έκδοση: (2010)

Eosinophilic bronchitis: an important cause of prolonged cough.
ανά: Brightling, C, κ.ά.
Έκδοση: (2000)

Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.
ανά: Brightling, C, κ.ά.
Έκδοση: (2000)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
ανά: Berry, M, κ.ά.
Έκδοση: (2007)

Non-eosinophilic corticosteroid unresponsive asthma.
ανά: Pavord, I, κ.ά.
Έκδοση: (1999)

Efficacy of Add-on Montelukast in Nonasthmatic Eosinophilic Bronchitis: The Additive Effect on Airway Inflammation, Cough and Life Quality
ανά: Wuping Bao, κ.ά.
Έκδοση: (2015-01-01)

Eosinophilic bronchitis: clinical features, management and pathogenesis.
ανά: Birring, S, κ.ά.
Έκδοση: (2003)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.
ανά: Bilocca, D, κ.ά.
Έκδοση: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
ανά: Haldar, P, κ.ά.
Έκδοση: (2009)

The significance of eosinophilic airway inflammation in asthma
ανά: Pavord, I, κ.ά.
Έκδοση: (2002)

Eosinophils in asthma and other allergic diseases.
ανά: Wardlaw, A, κ.ά.
Έκδοση: (2000)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
ανά: Kulkarni, N, κ.ά.
Έκδοση: (2010)

Airway hyperresponsiveness is dissociated from airway wall structural remodeling.
ανά: Siddiqui, S, κ.ά.
Έκδοση: (2008)

New insights into the role of the mast cell in asthma.
ανά: Brightling, C, κ.ά.
Έκδοση: (2003)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
ανά: Haldar, P, κ.ά.
Έκδοση: (2014)

Eosinophils in asthma and airway hyperresponsiveness.
ανά: Brightling, C, κ.ά.
Έκδοση: (2004)

Chapter 11. Mast cell localization within the airway smooth muscle: Relationship to airway hyperresponsiveness and other asthma phenotypes
ανά: Wardlaw, A, κ.ά.
Έκδοση: (2004)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
ανά: Shrimanker, R, κ.ά.
Έκδοση: (2017)

Mast-cell infiltration of airway smooth muscle in asthma.
ανά: Brightling, C, κ.ά.
Έκδοση: (2002)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
ανά: Haldar, P, κ.ά.
Έκδοση: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
ανά: Haldar, P, κ.ά.
Έκδοση: (2014)

The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma
ανά: Nair Parameswaran, κ.ά.
Έκδοση: (2011-03-01)

New insights into the relationship between airway inflammation and asthma.
ανά: Wardlaw, A, κ.ά.
Έκδοση: (2002)

Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma.
ανά: Brightling, C, κ.ά.
Έκδοση: (2003)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
ανά: Berry, M, κ.ά.
Έκδοση: (2005)

The relationship between clinical outcomes and medication adherence in difficult-to-control asthma.
ανά: Murphy, A, κ.ά.
Έκδοση: (2012)